Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with ...

Passing the baton: Kiran Mazumdar-Shaw (left), executive chairperson, Biocon, and niece Claire Mazumdar, chief executive ...

Shaw, founder and chairperson of Biocon , said on Tuesday that she plans a phased leadership transition over the next ​five years, with her niece Claire Mazumdar expected to eventually take over ‌as ...

The company’s market capitalisation stood at ₹59,673 crore, with over 2 lakh shares changing hands over the counter, compared to the two-week average of 0.77 lakh shares. Sign up for Fortune India's ...

Biocon said it will submit a comprehensive corrective and preventive action (CAPA) plan within the stipulated timeline and is confident all observations will be addressed fully and expeditiously.

Biocon's transformative journey under Kiran Mazumdar-Shaw highlights a significant succession plan and corporate restructuring for future growth.

At the time of filing this report, the stock of the Bangalore-based company was trading at Rs 240.10 apiece on the BSE, down ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Unveiled by Biocon Chairperson Kiran Mazumdar-Shaw, the programme is part of the Station Access and Mobility Program (STAMP), ...

Biocon has named Peter Bains its next CEO as the company looks to expand its presence in North America and beyond. As part of the move, which became effective Monday, Bains will step down from ...

Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.